Regenerx Biopharm In
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, develops pharmaceuticals from Thymosin beta 4 (Tß4) for tissue protection, repair, and regeneration. The company is developing RGN-259, a sterile and preservative-free eye drop that has completed Phase 3 clinical trial for the treatment of dry eye syndrome and neurotrophic keratitis. It has strategic partnerships with Lee's Pharmaceu… Read more
Regenerx Biopharm In (RGRX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2023: 0.051x
Based on the latest financial reports, Regenerx Biopharm In (RGRX) has a cash flow conversion efficiency ratio of 0.051x as of March 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-189.33K) by net assets ($-3.74 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Regenerx Biopharm In - Cash Flow Conversion Efficiency Trend (2014–2022)
This chart illustrates how Regenerx Biopharm In's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Regenerx Biopharm In Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Regenerx Biopharm In ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VR Factory Games SA
WAR:VRF
|
N/A |
|
Woodbois Ltd
LSE:WBI
|
-0.016x |
|
CQS Natural Resources Growth and Income plc
LSE:CYN
|
-0.001x |
|
Santa Rosa Resources Corp
V:STR-H
|
0.005x |
|
Okmin Resources, Inc.
OTCQB:OKMN
|
0.039x |
|
Eden Hotel Lanka PLC
CM:EDENN0000
|
N/A |
|
Loud Beverage Group Inc
PINK:LBEV
|
N/A |
|
Pri0r1ty Intelligence Group PLC
LSE:PR1
|
N/A |
Annual Cash Flow Conversion Efficiency for Regenerx Biopharm In (2014–2022)
The table below shows the annual cash flow conversion efficiency of Regenerx Biopharm In from 2014 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $-3.45 Million | $-940.72K | 0.273x | -38.52% |
| 2021-12-31 | $-2.23 Million | $-990.30K | 0.444x | +24.55% |
| 2020-12-31 | $-2.82 Million | $-1.01 Million | 0.357x | -26.68% |
| 2019-12-31 | $-2.34 Million | $-1.14 Million | 0.486x | +21.10% |
| 2018-12-31 | $-2.21 Million | $-888.29K | 0.402x | +149.29% |
| 2017-12-31 | $-4.12 Million | $-663.09K | 0.161x | -8.51% |
| 2016-12-31 | $-6.07 Million | $-1.07 Million | 0.176x | +125.97% |
| 2015-12-31 | $-6.74 Million | $-525.34K | 0.078x | -92.17% |
| 2014-12-31 | $-1.71 Million | $-1.70 Million | 0.995x | -- |